Source: International Congress 2019 – Tuberculosis: treatment and management
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. Rodina (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), D. Ivanova (Moscow, Russian Federation). Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens. 5278

Member's Comments

No comment yet.

Related content which might interest you: Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 Frequency of adverse reactions to first-line anti-tuberculosis chemotherapy in patients with relapse(RTB)and newly diagnosed tuberculosis(NDTB) Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Adverse effects in patients receiving therapy for multi-drug resistant tuberculosis in Latvia Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003 Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012 Adverse effects of anti-tuberculosis drugs in hemodialysis patients Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Adverse effects of chemotherapy in patients with multidrug-resistant tuberculosis with alcohol abuse and without one Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Adverse effects analysis results during anti-TB treatment among hemodialysis patients Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021 Adverse effects of MDR-TB treatment with a standardized regimen: A report from Iran Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010 Adverse effects of treatment in HIV-associated tuberculosis patients in Iran Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Chemotherapy efficacy in TB patients resistant to major and reserve drugs Source: Eur Respir J 2005; 26: Suppl. 49, 648s Year: 2005 Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Adverse events in the treatment of multidrug-resistant tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005 Thromboembolic events in lung cancer patients treated with platinum-based chemotherapy Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019